Werewolf Therapeutics (HOWL) Income towards Parent Company (2020 - 2026)

Werewolf Therapeutics has reported Income towards Parent Company for 7 years, with the latest figure at $7.0 million in Q2 2026.

• Income towards Parent Company for Q2 2026 came in at $7.0 million, up 138.68% year-over-year; the trailing twelve-month figure through Jun 2026 was -$34.8 million (up 51.63% YoY), and the FY2025 annual result was -$144.2 million, down 7.04% from the prior year.
• Income towards Parent Company climbed to $7.0 million in Q2 2026, from -$14.2 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $7.0 million in Q2 2026 and troughed at -$19.0 million in Q4 2024.
• A 5-year average of -$12.9 million and a median of -$14.5 million in 2022 frame the typical range for Income towards Parent Company.
• The widest annual swing landed in 2024, when Income towards Parent Company slumped 260.91%; it then soared 138.68% in 2026.
• A 5-year view of Income towards Parent Company shows it stood at -$12.0 million in 2022, then gained by 0.02% to -$12.0 million in 2023, then tumbled by 58.44% to -$19.0 million in 2024, then surged by 46.22% to -$10.2 million in 2025, then jumped by 168.08% to $7.0 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were $7.0 million in Q2 2026, -$14.2 million in Q1 2026, and -$10.2 million in Q4 2025.